ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Our ethics
  • ABPI Code of Practice

ABPI Code of Practice

The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies commitment to self-regulation and to operate in a professional, ethical and transparent manner. 

The 2019 Code is available here.  

The Prescription Medicines Code of Practice Authority (PMCPA) has also published the approved requirements of the 2021 Code along with a range of supporting materials.

The 2021 Code comes into operation on 1 July 2021; we will be publishing the final ABPI Code booklet closer to that date.

The next few months will see briefings and information being made available to help companies and stakeholders understand and implement the 2021 Code so they are ready for its implementation.

While the foundations of the Code remain the same, it is structured quite differently, and there are important new requirements and features to be aware of. The PMCPA supporting material includes a summary of the changes. 

The 2021 Code incorporates the new ABPI Principles. These set out the behaviours that embody the spirit of the Code, and the ABPI’s expectation is that companies start now in building these into their culture and ways of doing business.

The new ABPI Principles are: benefitting patients, acting with integrity, ensuring transparency, and treating everyone with respect. Senior leaders in companies are asked to champion the adoption of the new ABPI Principles, drive implementation across their organisation and ensure staff behave in a manner consistent with the principles.

There are many other changes to the detail of the 2021 Code, and you can find out more on the PMCPA website. 

Our ethics

  • ABPI Code of Practice
    • ABPI Code Consultation
  • Appropriate prescribing
  • Disclosure UK
  • Ethical responsibility
  • Patient & public involvement

RELATED LINKS

  • Code of Practice for the Pharmaceutical Industry 2019

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.